AbbVie: Ovarian Neoplasms trials

The registry lists 25 Ovarian Neoplasms studies with AbbVie as lead sponsor. 5 are open to participants now and 5 have results posted.

Phase 1 14Phase 2 7Phase 3 4No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid TumorsRecruitingNCT07807956Phase 1
• Study to Assess Prevalence of the Folate Receptor Alpha (FRa) in Adult Female Participants With Ovarian Cancer in Intercontinental (InterCon) CountriesRecruitingNCT07539844
• A Study to Evaluate Folate Receptor Alpha (FRα) Expression in Adult Participants With Ovarian, Fallopian Tube, and Primary Peritoneal Cancer in ItalyRecruitingNCT07407062
• A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian CancerRecruitingNCT07278336Phase 1
• A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian CancerRecruitingNCT07059845Phase 2
• Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube CancersCompletedNCT05041257Phase 2Results posted
• A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha ExpressionCompletedNCT04296890Phase 3Results posted
• A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube CancerCompletedNCT02631876Phase 3Results posted
• Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT02606305Phase 1/2Results posted
• Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedNCT02470585Phase 3Results posted
• A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha ExpressionActive, not recruitingNCT06365853Phase 2
• Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian CancerActive, not recruitingNCT05456685Phase 2
• Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal CancerActive, not recruitingNCT05445778Phase 3
• A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian CancerWithdrawnNCT03400306Phase 1
• Study of SC-003 Alone and in Combination With ABBV-181 in Subjects With Platinum-Resistant/Refractory Ovarian CancerTerminatedNCT02539719Phase 1
• Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian CancerCompletedNCT02483104Phase 1
• A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid TumorsCompletedNCT02033551Phase 1
• A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid TumorsCompletedNCT02009631Phase 1
• A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid TumorsCompletedNCT01853306Phase 1
• A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian CancerCompletedNCT01113957Phase 2
• Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin)CompletedNCT00635193Phase 1/2
• A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer PatientsCompletedNCT00526617Phase 1
• BB-10901 in Treating Patients With Relapsed or Refractory Solid TumorsCompletedNCT00346385Phase 1
• Study of Motexafin Gadolinium and Docetaxel for Advanced CancerCompletedNCT00120939Phase 1
• Study of Motexafin Gadolinium and Docetaxel for Advanced Solid TumorsCompletedNCT00080041Phase 1